A pharmaceutical company involved in developing treatments for schizophrenia, with a portfolio of 10 FDA-approved drugs, though it has no orphan drug designations.
0
Orphan Designations
10
FDA Approvals
Latest: VOYXACT (2025)
0
Active Trials
1
Rare Diseases
across 1 areas
0
News (30d)
Quiet
Otsuka America Pharmaceutical, Inc. is a company with 0 orphan drug designations across 1 rare disease, including 10 FDA-approved therapies. 2 active policy bills affect their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| schizophrenia | REXULTI | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/1
candidate diseases
0
avg importance: 0
2
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/1
candidate diseases
0
avg importance: 0
2
affecting portfolio